Skip to main content
. 2019 Jul 12;121(4):312–317. doi: 10.1038/s41416-019-0521-7

Fig. 3.

Fig. 3

Benefit for DFS with the addition of oxaliplatin to LV5FU2 in a all patients, b the MOSAIC low-risk patients, c the MOSAIC low-risk patients after CEA stratification, d the MOSAIC high-risk patients, and e the MOSAIC high-risk patients after CEA stratification. Figure 3 abbreviations: Ox oxaliplatin; +ox with oxaliplatin; Ox without oxaliplatin